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ABSTRACT
We present herein the case of a patient with solitary
metachronous contralateral adrenal metastasis from renal
cell cancer. The patient had undergone left radical ne-
phrectomy and adrenalectomy for localized renal cancer 7
years previously. Laparoscopic transperitoneal right adre-
nalectomy was performed. The postoperative period was
uneventful. Histology showed right adrenal metastasis
from renal cancer. At 6-month follow-up, there was no
evidence of recurrence.
Key Words: Laparoscopic adrenalectomy, Adrenal metas-
tasis, Renal cancer.
INTRODUCTION
Renal cell carcinoma (RCC) is the most common malig-
nancy involving the kidney.1 Nearly 20% to 30% of pa-
tients with renal cell carcinoma have distant metastasis at
presentation.2 Although RCC can metastasize to almost
every organ, the most common metastatic sites are the
lung parenchyma (50% to 60%),3 bone (30% to 40%),4 the
liver (30% to 40%), and the brain (5%).5 Other rare sites of
metastasis include the pancreas6,7 and parotid gland.8
Whereas metastasis of RCC to different sites is not uncom-
mon, contralateral adrenal metastasis is very rare.
The average patient survival of metastatic RCC is about 4
months, and only 10% of these patients survive for 1 year.
There is a small subset of patients where solitary metas-
tasis is present either at the time of presentation or devel-
ops during follow-up after nephrectomy; these patients
have a better survival.
Although adrenal metastases from RCC are rarely diag-
nosed in patients, these are not uncommonly found at
autopsy.9,10 These are rare lesions that are diagnosed syn-
chro-nously with the renal tumor. Most of the cases are in
patients with multiple metastases. Only a few are detected
metachronously.
Surgical removal of metastatic lesions is the only known
effective treatment in patients with solitary metastasis,
with 14% to 38% surviving 5 years or more.11–13 Several
investigators have re-ported better survival for metastatic
RCC in pa-tients who have a solitary metastasis that ap-
pears more than 18 months after nephrectomy.11,12,14
We present herein a case of large, metachronous, con-
tralateral adrenal metastasis from primary left renal cell
adenocarcinoma that was removed completely by the
laparoscopic approach. The patient had left nephrectomy
and left adrenalectomy 7 years earlier.
CASE REPORT
A 44-year-old Caucasian man underwent left radical ne-
phrectomy, including ipsilateral adrenalectomy in 1999,
for a left renal mass and did not receive adjuvant chemo-
therapy. The histology report showed adenocarcinoma.
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CASE REPORTThe patient did well until 7 years later, when an annual
follow-up abdominal computerized tomography (CT)
scan revealed a 9x8-cm hypervascular mass in the right
adrenal (Figure 1). Magnetic resonance imaging (MRI)
confirmed a malignant-appearing mass measuring 9x8cm
arising from the right adrenal. After intravenous injection
of gadolinium, the mass showed a hypervascular mass
(Figure 2). No evidence was found of calcification or
invasion of adjacent tissues or organs. No other abdominal
abnormalities were noted.
The patient was in good health and asymptomatic. Blood
pressure was within the normal range. At physical examina-
tion, no abnormalities were found. Radiography of the tho-
rax and an electrocardiogram were normal. Routine blood
and urine tests as well as tumor markers showed no abnor-
mality. On metabolic evaluation, 24-hour urine collection for
17-ketosteroids, 17-hydroxycorticoids, metanephrines, corti-
sol, and vanillylmandelic acid were within normal limits.
Surgical Technique
The laparoscopic approach was chosen. We prefer a
transperitoneal lateral decubitus approach as the best for
maximal exposure of the gland and major vessels. Using
the Hasson technique, a 12-mm trocar, one 10-mm trocar,
one 12-mm, and one 5-mm trocar were inserted below the
costal margin. Laparoscopic exploration of the abdominal
cavity revealed no abnormalities, and the tumor was easily
identified. The right triangular ligament and the retroper-
itoneal liver attachments were cauterized and divided to
allow liver retraction. After dividing the retroperitoneum,
the inferior vena cava (IVC) was identified. The inferior
periadrenal fat was carefully dissected from the upper
pole of the right kidney and the renal vein identified. The
Figure 1. Abdominal computed tomographic scan suggested possible metastatic tumor to the right adrenal gland.
Figure 2. Abdominal magnetic resonance image showing the
right adrenal mass.
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double-clipped, and divided. The inferior and superior
adrenal vessels were cauterized with ultrasonic scissors
following division of the right adrenal vein. The entire
specimen was placed intact into a laparoscopy entrap-
ment sack and extracted through an extension of the
incision done for the Hasson technique.
The pneumoperitoneum was aspirated through ports be-
fore specimen extraction. The port-site wounds were irri-
gated with a solution of povidone iodine 10% followed by
normal saline. The fascia of the 3 trocar sites was closed
with a 1–0 Prolene stitch. The procedure lasted 3 hours,
the estimated intraoperative blood loss was 600 mL, and
the patient was not transfused. The surgical specimen
measured 9x8 cm and weighed 330 g.
The patient was started on immediate steroid replace-
ment, with the hydrocortisone dosage tapered to 20mg 3
times daily, in addition to 0.1 mg fludrocortisone daily.
The postoperative period was uneventful, and the patient
was discharged on the second postoperative day with
bowel function returned to normal and the patient able to
return to normal physical activity.
Histology confirmed a metastatic tumor from renal aden-
ocarcinoma.
Six months after the procedure, there was no evidence of
recurrence on abdominal CT scan, and the cosmetic result
was satisfactory.
DISCUSSION
RCC metastasis may be found synchronously with the
primary tumor or in various organs many years after the
primary lesion has been treated. Metastasis of RCC to the
contralateral adrenal gland is very rare. In reviews of the
literature, the majority of the cases described involved
synchronous metastasis.15–17 Most metachronous metasta-
ses are identified in the first or second year after nephrec-
tomy, and 25% of patients develop metastatic disease
within 5 years of nephrectomy.18 Metastasis has been
diagnosed as late as 23 years after nephrectomy.19,20
Adrenal metastasis is rarely diagnosed during life. In fact,
clinical signs and symptoms are rare in these patients. How-
ever, recently improvements in noninvasive radiological
techniques, such as computerized tomography (CT), selec-
tive arteriography, and magnetic resonance imaging (MRI),
have improved the clinical detection of metastatic lesions.
CT-guided needle biopsy is currently available in some cen-
ters, including ours. Biopsy of adrenal masses may be help-
ful in doubtful cases, although in general the diagnosis has
been problematic. However, several concerns have been
raised, among which are that the capsule of an adrenal
tumor is thin and the lesion tends to be brittle. As a result, an
intrinsic risk exists of hemorrhage.21,22
In some cases, failure to use routine imaging studies might
explain the delayed detection. However, a more possible
explanation for the delayed diagnosis of metastasis is that
some metastases can be very slow growing.21
RCC is known for its varied presentation and its propensity to
metastasize by way of both venous and lymphatic routes.
Conversely, it is believed that hematogenous metastasis to
the adrenal gland is more common than lymphogenous
extension due to the rich blood supply of the adrenal gland
and its high blood volume-to-unit weight ratio.23
The prognosis for patients with untreated widely metastatic
renal cell carcinoma is dismal. Nevertheless, in patients with
solitary or limited metastases, removal of the RCC metastasis
is associated with prolonged survival. Studies have shown
significant differences in survival between synchronous and
metachronous solitary metastases, the synchronous group
being the worst.12,14,24 Many studies have reported that pa-
tients with adrenal metastasis occurring a long time after
nephrectomy had a better prognosis than those with a short
interval to diagnosis. Several investigators have noted better
survival for metastatic RCC in patients who have a solitary
metastasis that appears more than 18 months after nephrec-
tomy.11,12,14,25,26 In other studies, a better prognosis has been
reported in patients with a disease-free interval of more than
12 months.27 Furthermore for some investigators, the dis-
ease-free interval required for better survival is only 6
months. The observation of poorer survival most likely is an
indicator of tumor biology.
After metastasectomy, overall median survival ranges from
26 months to 45 months. The 3-year survival rate ranges
from 35% to 60% and 5-year survival ranges from 14% to
38%.11,16,17
A broad range of treatments, including chemotherapy,
hormonal therapy, and radiotherapy, have failed to mark-
edly im-prove survival. Moreover, despite the early prom-
ising results with immunotherapy, a complete response
occurs in less than 15%. Therefore, aggressive treatment of
such lesions is indicated. Complete extirpation of all tu-
mor clearly is important.17,19
Laparoscopic adrenalectomy has been performed success-
fully transperitoneally and retroperitoneally to treat a va-
riety of benign adrenal pathological conditions.
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ative discomfort, decreased hospital stay, less postoperative
disability, and a lower rate of complications. Few absolute
contraindications exist for laparoscopic adrenalectomy, and
most of them are not specific to adrenal surgery. Large but
well-encapsulated adrenal masses without evidence of local
invasion can be removed laparoscopically.28 The lateral
transabdominal approach offers the best visualization of ma-
jor vessels adjacent to the adrenals.29
The role of laparoscopic surgery for malignant adrenal
tumors is controversial, because few data exist in the
literature for this rare disease.
Concerns have focused on the possibility of tumor rupture
due to manipulation with laparoscopic instruments with
the attendant fear of disseminating malignant cells inside
the peritoneal cavity.
Three cases of diffuse peritoneal dissemination and death
of patients who underwent laparoscopic adrenalectomy
for adrenal cancer have been reported.30 Moreover in a
larger study, 13 patients, 6 with adrenal cortical carcinoma
and 7 with metastasis, were reported. The mean size of the
malignant lesions was 5.9cm. The mean follow-up was 30
months, during which 3 patients died, 1 from endoperi-
toneal and trocar port-site seeding.31 In another study, 31
patients underwent 33 laparoscopic adrenalectomies. In
26 cases, metastatic cancer and primary adrenal malig-
nancy were present in 7. Follow-up was 26 months, dur-
ing which 15 patients died. Local recurrence was noted in
7 patients. However, no port-site metastases occurred.
The 5-year survival reached 40%.32
On the contrary, Heniford and colleagues in a review of
10 patients with metastatic adrenal tumors and 1 patient
with adrenocortical carcinoma reported no local or port-
site recurrence at a mean follow-up of 8.3 months.33 Fur-
thermore, there is another study of 8 patients with malig-
nancies, 4 with cortical carcinomas and 4 with metastases
(from renal carcinoma, breast carcinoma, leiomyosarcoma
and rhabdoid sarcoma). Mean follow-up was 40.5 months.
During follow-up, 3 patients with cortical carcinomas
were disease-free and 1 died of a stroke, 2 had metastases
(1 leiomyosarcoma and 1 breast carcinoma) 1 died of
disease, and 2 were disease free. No port-site metastases
occurred.34 In the largest series reported in the literature,35
21 patients who underwent laparoscopic adrenalectomy
for malignant tumors were reviewed. Three locoregional
recurrences occurred 1 to 2.5 years after resection (2 local
and 1 lymph node metastasis) in the 6 patients with
primary adrenal cancer. There were no local recurrences
in the 13 patients with metastatic adrenal tumors.
A study has focused on solitary adrenal gland metastasis in
patients operated on for nonsmall cell lung cancer. Eleven
patients had solitary adrenal metastases. All of them un-
derwent laparoscopic adrenalectomy. Three were still
alive and well at 37 months to 80 months after the lung
resection. One patient (who underwent bilateral adrenal-
ectomy) was still alive at 44 months with local relapse.
Two patients died 5 and 6 months after the adrenalectomy
of other causes; 1 died at 14 months for local and systemic
relapse, and the remaining 3 patients died at 12 to 38
months for systemic relapse.36
CONCLUSION
We report a case of metachronous, contralateral metasta-
sis from left renal adenocarcinoma, occurring 7 years after
curative radical nephrectomy, including left adrenalec-
tomy. Despite the large size of the tumor, laparoscopic
adrenalectomy was successfully performed. Laparoscopic
adrenalectomy resulted in a short hospital stay, minimal
blood loss, and minimal postoperative analgesic require-
ment. There was no other evidence of metastatic disease
at adrenalectomy, or at 6-month follow-up.
Patients having metachronous, contralateral adrenal me-
tastasis from renal cell carcinoma benefit from the surgical
resection of the lesion. Patients with a disease-free interval
of more than 1 year before development of solitary me-
tastasis appear to have better survival. The laparoscopic
approach, having more advantages versus open surgery,
is feasible but necessitates experience in advanced lapa-
roscopic surgery. The benefits to the patient of earlier
ambulation, decreased pain, better cosmetic results, and
lower percentage of incisional hernia must be weighed
against the as yet unknown long-term results. Extensive
experience in advanced laparoscopic techniques and
open adrenal surgery are mandatory to manipulate and
excise laparoscopically malignant tumors.
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